BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of deletions of derivative chromosome 9. METHODS: A study was undertaken to investigate the prognostic impact of deletions of derivative chromosome 9 in 353 patients with CML receiving the second generation tyrosine kinase inhibitors (TKIs) nilotinib (n = 161) or dasatinib (n = 192). RESULTS: Deletion of derivative chromosome 9 status was determined in 245 (69%). Twenty-eight (11%) patients, 22 in chronic phase, 4 in accelerated phase, and 2 in blast phase, carried deletions of derivative chromosome 9, including 17 receiving nilotinib and 11 receiving dasatinib (P = .47). Overall survival (OS) at 24 months was similar between patients with or without deletions of derivative chromosome 9 (70% vs 71%, P = .76). For patients in chronic phase, no significant differences in overall major cytogenetic response (77% vs 82%, P = .57) or complete cytogenetic response (77% vs 81%, P = .71) rates were observed between patients with or without deletions of derivative chromosome 9. At 24 months, patients with CML in chronic phase without deletions of derivative chromosome 9 had improved event-free survival (EFS) (88% vs 66%, P = .07) and OS (96% vs 82%; P = .08) compared with those carrying deletions of derivative chromosome 9. However, multivariate analysis established second-line versus frontline second generation TKI therapy as the only adverse prognostic factor for EFS and increased bone marrow blast burden and older age as independent adverse prognostic factors for OS. CONCLUSIONS: Deletions of derivative chromosome 9 do not appear to be an independent risk factor for survival among patients with CML in chronic phase receiving second generation TKIs.
BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of deletions of derivative chromosome 9. METHODS: A study was undertaken to investigate the prognostic impact of deletions of derivative chromosome 9 in 353 patients with CML receiving the second generation tyrosine kinase inhibitors (TKIs) nilotinib (n = 161) or dasatinib (n = 192). RESULTS: Deletion of derivative chromosome 9 status was determined in 245 (69%). Twenty-eight (11%) patients, 22 in chronic phase, 4 in accelerated phase, and 2 in blast phase, carried deletions of derivative chromosome 9, including 17 receiving nilotinib and 11 receiving dasatinib (P = .47). Overall survival (OS) at 24 months was similar between patients with or without deletions of derivative chromosome 9 (70% vs 71%, P = .76). For patients in chronic phase, no significant differences in overall major cytogenetic response (77% vs 82%, P = .57) or complete cytogenetic response (77% vs 81%, P = .71) rates were observed between patients with or without deletions of derivative chromosome 9. At 24 months, patients with CML in chronic phase without deletions of derivative chromosome 9 had improved event-free survival (EFS) (88% vs 66%, P = .07) and OS (96% vs 82%; P = .08) compared with those carrying deletions of derivative chromosome 9. However, multivariate analysis established second-line versus frontline second generation TKI therapy as the only adverse prognostic factor for EFS and increased bone marrow blast burden and older age as independent adverse prognostic factors for OS. CONCLUSIONS: Deletions of derivative chromosome 9 do not appear to be an independent risk factor for survival among patients with CML in chronic phase receiving second generation TKIs.
Authors: J de la Fuente; K Merx; E J Steer; M Müller; R M Szydlo; O Maywald; U Berger; R Hehlmann; J M Goldman; N C Cross; J V Melo; A Hochhaus Journal: Blood Date: 2001-11-01 Impact factor: 22.113
Authors: Nasios Fourouclas; Peter J Campbell; Anthony J Bench; Soheila Swanton; E Joanna Baxter; Brian Jp Huntly; Anthony R Green Journal: Haematologica Date: 2006-07 Impact factor: 9.941
Authors: Brian J P Huntly; Anthony J Bench; Eric Delabesse; Alistair G Reid; Juan Li; Mike A Scott; Lynda Campbell; Jennie Byrne; Eleanor Pinto; Andre Brizard; Deitger Niedermeiser; Elizabeth P Nacheva; Francois Guilhot; Michael Deininger; Anthony R Green Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: B J Huntly; A G Reid; A J Bench; L J Campbell; N Telford; P Shepherd; J Szer; H M Prince; P Turner; C Grace; E P Nacheva; A R Green Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: Zhenya Tang; Gokce A Toruner; Guilin Tang; C Cameron Yin; Wei Wang; Shimin Hu; Beenu Thakral; Sa A Wang; Roberto N Miranda; Joseph D Khoury; L Jeffrey Medeiros Journal: Mod Pathol Date: 2020-05-13 Impact factor: 7.842
Authors: Z Gong; L J Medeiros; J E Cortes; L Zheng; J D Khoury; W Wang; G Tang; S Loghavi; R Luthra; W Yang; H M Kantarjian; S Hu Journal: Blood Cancer J Date: 2017-07-14 Impact factor: 11.037